Verification evidence is still being completed.
PDF / print export
Noema Pharma AG
Basel, Switzerland
- Verified lead
- Ilise Lombardo
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- CNS and Rare Neurology Therapeutics, Orphan Indications, and Ex-Roche Asset Development
- Review cycle
- 24 April 2026
- Full address
- Barfusserplatz 3, 4051 Basel, Switzerland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Noema Pharma press release appointing Ilise Lombardo MD as Chief Executive Officer in June 2023.
- Editorial note
- Basel clinical-stage CNS biotech with named CEO since June 2023, Sofinnova-backed 103 million EUR financing, and a pipeline of orphan neurological programs.
CNS and Rare Neurology Therapeutics, Orphan Indications, and Ex-Roche Asset Development
Sofinnova portfolio, 103 million EUR financing record, Public CEO appointment release
Basel clinical-stage CNS biotech with named CEO since June 2023, Sofinnova-backed 103 million EUR financing, and a pipeline of orphan neurological programs.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Basel, Switzerland
Noema Pharma AG
CNS and Rare Neurology Therapeutics, Orphan Indications, and Ex-Roche Asset Development · Clinical-stage CNS therapeutics
Basel clinical-stage CNS biotech with named CEO since June 2023, Sofinnova-backed 103 million EUR financing, and a pipeline of orphan neurological programs.
- Lead
- Ilise Lombardo (verified ↗)
- Address
- Barfusserplatz 3, 4051 Basel, Switzerland (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Clinical-stage CNS therapeutics
- Capabilities
- CNS and Rare Neurology Drug Development · Orphan Neurological Indications · Ex-Roche Asset Advancement
- Founded
- 2020
- Headcount
- 11-50
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Ilise Lombardo
Chief Executive Officer
Full addressBarfusserplatz 3, 4051 Basel, Switzerland
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
Noema Pharma corporate information listing Barfusserplatz 3 in Basel.
Open sourceClinical-stage CNS therapeutics
Basel, Switzerland. CNS and Rare Neurology Therapeutics, Orphan Indications, and Ex-Roche Asset Development. Review completed on 24 Apr 2026.
Swissmedic, FDA, and EMA for clinical oversight
Sofinnova portfolio, 103 million EUR financing record, Public CEO appointment release
CNS and Rare Neurology Therapeutics, Orphan Indications, and Ex-Roche Asset Development
Basel clinical-stage CNS biotech with named CEO since June 2023, Sofinnova-backed 103 million EUR financing, and a pipeline of orphan neurological programs.
Editorial note
Noema Pharma is a Basel CNS biotech with a named CEO since June 2023, a Sofinnova-backed 103 million EUR financing, and a pipeline of orphan neurological programs derived from ex-Roche assets.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
CNS and Rare Neurology Drug Development
Orphan Neurological Indications
Ex-Roche Asset Advancement
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
CNS drug-development workflow
Clinical trial operations
Partner CDMO supply
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Noema Pharma AG located?
- Noema Pharma AG operates from Barfusserplatz 3, 4051 Basel, Switzerland, Basel, Switzerland.
- Who runs Noema Pharma AG?
- Noema Pharma AG is led by Ilise Lombardo, Chief Executive Officer. Verified 24 Apr 2026.
- What does Noema Pharma AG do?
- Basel clinical-stage CNS biotech with named CEO since June 2023, Sofinnova-backed 103 million EUR financing, and a pipeline of orphan neurological programs. Core capabilities: CNS and Rare Neurology Drug Development, Orphan Neurological Indications, Ex-Roche Asset Advancement.
Editorial context
Related technical briefs
Briefs that name Basel as a covered market or city.